- Free from Publisher A Basu, MD Jensen, F McCann, D … - Diabetes Care, 2006 - Am Diabetes Assoc RESULTS—Pioglitazone increased (P < 0.001 from baseline) total body water
(+2.4 ± 0.5 l) accounting for 75% of the total weight gain (+3.1 ± 2.0 kg) but
did not alter vascular endothelial growth factor concentrations. Total ... Cited by 54 - Related articles - BL Direct - All 6 versions
G Derosa, AFG Cicero, A Gaddi, PD Ragonesi, … - Diabetes research and clinical practice, 2005 - Elsevier A total of 87 completed the study (pioglitazone n = 45 or rosiglitazone n = 42).
Body mass index increased after 12 months compared to baseline (p < 0.05) in
both groups. A significant decrease in glycated haemoglobin (HbA 1c ) was ... Cited by 61 - Related articles - All 9 versions
G Derosa, AFG Cicero, A D'Angelo, A Gaddi, PD … - Hypertension Research, 2005 - nature.com The aim of our study was to compare the long-term effect of pioglitazone and
rosiglitazone on blood pressure control of diabetic patients with metabolic
syndrome treated with glimepiride. We evaluated 91 type 2 diabetic patients ... Cited by 36 - Related articles - BL Direct - All 5 versions
AJ Karter, AT Ahmed, J Liu, HH Moffet, MM … - Diabetic Medicine, 2005 - interscience.wiley.com Methods A cohort study of all patients in the Kaiser Permanente Medical Care
Program with Type 2 diabetes (Kaiser Permanente Northern California Diabetes
Registry) who initiated any diabetes pharmacotherapy (n = 23 440) between ... Cited by 69 - Related articles - BL Direct - All 4 versions
DJ Betteridge, B Verges - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: The aim of this study was to determine the long-term
effects of pioglitazone add-on to metformin or sulphonylurea on plasma lipids
and lipo- proteins. Materials and methods: The effects of piogli- tazone ... Cited by 37 - Related articles - BL Direct - All 3 versions
G Derosa, A D'Angelo, PD Ragonesi, L … - Journal of Clinical Pharmacy and Therapeutics, 2006 - interscience.wiley.com Methods: This 12-month, multicentre, double-blind, randomized, controlled,
parallel-group trial was conducted at three study sites in Italy. We assessed
patients with type 2 diabetes mellitus (duration ≥6 months) and with ... Cited by 49 - Related articles - BL Direct - All 6 versions
[CITATION] Do thiazolidinediones cause heart failure
M Tan, D Johns, G González Gálvez, O … - Clinical therapeutics, 2004 - Elsevier Methods: This was a multicenter, 52-week, double-blind, parallel-group trial.
Patients were randomized to receive monotherapy with either glimepiride (2 mg QD
initially) or pioglitazone (15 mg QD initially). Doses were titrated ... Cited by 27 - Related articles - All 3 versions
B Charbonnel, G Schernthaner, P Brunetti, … - Diabetologia, 2005 - Springer Abstract Aims/hypothesis: The aim of this analysis was to examine the long-term
effects of pioglitazone or gliclazide addition to failing metformin monotherapy
and pioglitazone or metformin addition to failing sulphonylurea monother- ... Cited by 96 - Related articles - All 5 versions
SR Smith, L de Jonge, J Volaufova, Y Li, H … - Metabolism, 2005 - Elsevier We performed a randomized, double-blind, placebo-controlled trial in 48 men and
women with type 2 diabetes who had not previously received treatment with TZDs.
Patients were treated for 24 weeks with 45 mg/d of pioglitazone or a ... Cited by 70 - Related articles - All 9 versions
